Human Reproduction, Vol. 17, No. 2, 332-336,
February 2002
© 2002 European Society of Human Reproduction and Embryology
Pharmacokinetics of different routes of administration of misoprostol
1 Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China and 2 Department of Pediatrics, Philipps University Marburg, Deutschhausstr, Germany
BACKGROUND: The pharmacokinetic parameters of four different routes of administration of a single dose of 400 µg of misoprostol were studied. METHODS: A total of 40 women undergoing termination of pregnancy by suction evacuation was randomized by computer model to receive 400 µg of misoprostol by one of four routes: (i) sublingual (ii) oral (iii) vaginal and (iv) vaginal with addition of water. Venous blood samples were taken at 0, 1, 2, 5, 10, 20, 30, 45, 60, 120, 240 and 360 min after the administration of misoprostol. Misoprostol acid (MPA) was determined in serum samples using gas chromatography/tandem mass spectrometry. RESULTS: Sublingual misoprostol achieved the highest serum peak concentration (Cmax) (574.8 ± 250.7 pg/ml) of MPA and this was significantly higher than those in the other groups [Oral: 287.6 ± 144.3 pg/ml (P < 0.01), vaginal: 125.2 ± 53.8 pg/ml (P < 0.001) and vaginal with water: 162.8 ± 57.1 pg/ml (P < 0.001)]. The time to peak concentration (Tmax) was similar in both the sublingual (26.0 ± 11.5 min) and oral groups (27.5 ± 14.8 min) and was significantly shorter than those in both vaginal groups. The area under the MPA concentration versus time curve up to 360 min in the sublingual group (743.7 ± 291.2 pg·h/ml) was significantly greater than those in oral (402.8 ± 151.6 pg·h/ml, P < 0.05) and vaginal (433.7 ± 182.6 pg·h/ml, P < 0.05) groups, but no significant difference was found between sublingual and vaginal administration if water (649.3 ± 333.8 pg·h/ml) was added. CONCLUSION: The new sublingual route of administration of misoprostol demonstrated a great potential to be developed into a method of medical abortion.
Key words: misoprostol/oral/pharmacokinetics/sublingual/vaginal
3 6/F, Professorial Block, Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, 102, Pokfulam Road, Hong Kong SAR, China. E-mail: ostang{at}graduate.hku.hk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. L. Powers, D. A. Wing, D. Carr, K. Ewert, and M. D. Spirito Pharmacokinetic Profiles of Controlled-Release Hydrogel Polymer Vaginal Inserts Containing Misoprostol J. Clin. Pharmacol., January 1, 2008; 48(1): 26 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Saav, A. Aronsson, L. Marions, O. Stephansson, and K. Gemzell-Danielsson Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial Hum. Reprod., October 1, 2007; 22(10): 2647 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aronsson, C. Fiala, O. Stephansson, F. Granath, B. Watzer, H. Schweer, and K. Gemzell-Danielsson Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol Hum. Reprod., July 1, 2007; 22(7): 1912 - 1918. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lalitkumar, M. Bygdeman, and K. Gemzell-Danielsson Mid-trimester induced abortion: a review Hum. Reprod. Update, January 1, 2007; 13(1): 37 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. R. Meckstroth, A. K. Whitaker, S. Bertisch, A. B. Goldberg, and P. D. Darney Misoprostol Administered by Epithelial Routes: Drug Absorption and Uterine Response. Obstet. Gynecol., September 1, 2006; 108(3): 582 - 590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. F. Rayburn, B. L. Powers, T. F. Plasse, D. Carr, and M. Di Spirito Pharmacokinetics of a Controlled-Release Misoprostol Vaginal Insert at Term Reproductive Sciences, February 1, 2006; 13(2): 112 - 117. [Abstract] [PDF]
|
|
|
|
|
|
O. S. Tang, C. Y.T. Ong, K. Y. Tse, E. H.Y. Ng, S. W.H. Lee, and P. C. Ho A randomized trial to compare the use of sublingual misoprostol with or without an additional 1 week course for the management of first trimester silent miscarriage Hum. Reprod., January 1, 2006; 21(1): 189 - 192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fiala, A. Aronsson, F. Granath, O. Stephansson, H.W. Seyberth, B. Watzer, and K. Gemzell-Danielsson Pharmacokinetics of a novel oral slow-release form of misoprostol Hum. Reprod., December 1, 2005; 20(12): 3414 - 3418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Tang, C. C.W. Chan, A. S.Y. Kan, and P. C. Ho A prospective randomized comparison of sublingual and oral misoprostol when combined with mifepristone for medical abortion at 12-20 weeks gestation Hum. Reprod., November 1, 2005; 20(11): 3062 - 3066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Yilmaz, S. Kelekci, I. E. Ertas, S. Kahyaoglu, M. Ozel, N. Sut, and N. Danisman Misoprostol moistened with acetic acid or saline for second trimester pregnancy termination: a randomized prospective double-blind trial Hum. Reprod., November 1, 2005; 20(11): 3067 - 3071. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Hoj, P. Cardoso, B. B. Nielsen, L. Hvidman, J. Nielsen, and P. Aaby Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial BMJ, October 1, 2005; 331(7519): 723. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Lin, F. S. Nuthalapaty, A. R. Carver, A. S. Case, and P. S. Ramsey Misoprostol for Labor Induction in Women With Term Premature Rupture of Membranes: A Meta-Analysis Obstet. Gynecol., September 1, 2005; 106(3): 593 - 601. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fiala, A. Aronsson, O. Stephansson, and K. Gemzell-Danielsson Effects of slow release misoprostol on uterine contractility in early pregnancy Hum. Reprod., September 1, 2005; 20(9): 2648 - 2652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Hamoda, P. W. Ashok, G. M.M. Flett, and A. Templeton A randomized trial of mifepristone in combination with misoprostol administered sublingually or vaginally for medical abortion at 13-20 weeks gestation Hum. Reprod., August 1, 2005; 20(8): 2348 - 2354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. B. Wolf, L. Sanchez-Ramos, and A. M. Kaunitz Sublingual Misoprostol for Labor Induction: A Randomized Clinical Trial Obstet. Gynecol., February 1, 2005; 105(2): 365 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bhullar, S. J. Carlan, J. Hamm, N. Lamberty, L. White, and K. Richichi Buccal Misoprostol to Decrease Blood Loss After Vaginal Delivery: A Randomized Trial Obstet. Gynecol., December 1, 2004; 104(6): 1282 - 1288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Fernandez, J.D. Alby, C. Tournoux, A. Chauveaud-Lambling, R. deTayrac, R. Frydman, and R. Porcher Vaginal misoprostol for cervical ripening before operative hysteroscopy in pre-menopausal women: a double-blind, placebo-controlled trial with three dose regimens Hum. Reprod., July 1, 2004; 19(7): 1618 - 1621. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.-U. Khan, H. El-Refaey, S. Sharma, D. Sooranna, and M. Stafford Oral, Rectal, and Vaginal Pharmacokinetics of Misoprostol Obstet. Gynecol., May 1, 2004; 103(5): 866 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Tang, K. H. Mok, and P. C. Ho A randomized study comparing the use of sublingual to vaginal misoprostol for pre-operative cervical priming prior to surgical termination of pregnancy in the first trimester Hum. Reprod., May 1, 2004; 19(5): 1101 - 1104. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Saxena, S. Salhan, and N. Sarda Comparison between the sublingual and oral route of misoprostol for pre-abortion cervical priming in first trimester abortions Hum. Reprod., January 1, 2004; 19(1): 77 - 80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aronsson, M. Bygdeman, and K. Gemzell-Danielsson Effects of misoprostol on uterine contractility following different routes of administration Hum. Reprod., January 1, 2004; 19(1): 81 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Tang, C. C.W. Chan, E. H.Y. Ng, S. W.H. Lee, and P. C. Ho A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation Hum. Reprod., November 1, 2003; 18(11): 2315 - 2318. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Dickinson and S. F. Evans A Comparison of Oral Misoprostol With Vaginal Misoprostol Administration in Second-Trimester Pregnancy Termination for Fetal Abnormality Obstet. Gynecol., June 1, 2003; 101(6): 1294 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. S. Tang, W. N. T. Lau, E. H. Y. Ng, S. W. H. Lee, and P. C. Ho A prospective randomized study to compare the use of repeated doses of vaginal with sublingual misoprostol in the management of first trimester silent miscarriages Hum. Reprod., January 1, 2003; 18(1): 176 - 181. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-S. Chong, S. Chua, and S. Arulkumaran Sublingual misoprostol for first trimester termination of pregnancy: safety concerns Hum. Reprod., October 1, 2002; 17(10): 2777 - 2777. [Full Text] [PDF]
|
|
|
|
|
|
O.-S. Tang Sublingual misoprostol for first trimester termination of pregnancy: safety concerns Hum. Reprod., October 1, 2002; 17(10): 2778 - 2778. [Full Text] [PDF]
|
|
|
|
|
|
H. Honkanen, S. Ranta, O. Ylikorkala, and O. Heikinheimo The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy Hum. Reprod., September 1, 2002; 17(9): 2315 - 2319. [Abstract] [Full Text] [PDF]
|
|